Pfizer Selects Biologics, Inc. as Limited Distribution Network Partner (LDN)

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., an integrated oncology services company has been selected as a Limited Distribution Network (LDN) partner for Pfizer’s Inlyta which was approved by the FDA on January 27, 2012. Inlyta is indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes within the kidney. Inlyta works by blocking certain proteins called kinases that play a role in tumor growth and cancer progression. The recommended dose for Inlyta is 5mg taken orally two times a day. Clinical trial results showed a median progression-free survival of 6.7 months compared to 4.7 months with a standard treatment.

“We are committed to delivering the highest standard of care to patients and are excited to partner with Pfizer in providing another option to patients battling renal cell carcinoma.”

Biologics encompasses patient access, specialty pharmacy and care continuum services to provide a comprehensive solution that improves the patient experience and accelerates access to appropriate care. Recognized for its high-touch patient care model, Biologics’ oncology pharmacy services group includes a clinically relevant team with expertise in complex therapies to ensure patient adherence and compliance. As a result of its commitment to supporting cancer patients, Biologics has extensive prescriber relationships across the United States.

“It’s an honor to be selected as a Limited Distribution Network partner for Pfizer’s Inlyta,” said Stuart Frantz, Chief Executive Officer and President of Biologics, Inc. “We are committed to delivering the highest standard of care to patients and are excited to partner with Pfizer in providing another option to patients battling renal cell carcinoma.”

About Biologics: Biologics, Inc. is an integrated oncology services company with an innovative business model that brings together the many complex components of cancer care to provide a patient-focused platform for managing the financial, emotional and physical burdens of cancer treatment. Biologics is at the center of the rapidly changing oncology environment to support treatment modalities, clinical outcomes and informatics and leverage established relationships with oncology clinicians, patients, payors, researchers and manufacturers. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Biologics, Inc. is headquartered in Cary, N.C.